Showing 6141-6150 of 8829 results for "".
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Teledermatology App Teams Up with Dermatologistshttps://practicaldermatology.com/news/20141002-teledermatology_company_teams_up_with_dermatologists/2459098/A new teledermatology app is partnering with board- and state-certified dermatologists to assist patients with on-the-spot information regarding the detection and evaluation of skin disease in early stages. Having launched already in 13 states, Klara has partnered up with Dr. Mark Kaufmann, MD, Asso
- Ranbaxy Launches Absorica 25mg and 35mg Capsuleshttps://practicaldermatology.com/news/20141001-ranbaxy_launches_absorica_25mg_and_35mg_capsules/2459099/Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, launched Absorica (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. Absorica, according to the company, has become the most prescribe
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- Celgene's Otezla Approved for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140924-celgenes_otezla_approved_for_moderate_to_severe_plaque_psoriasis/2459107/The FDA has approved Celgene's Otezla (apremilast), an oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor approved for th
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Boardhttps://practicaldermatology.com/news/20140922-provectus_biopharmaceuticals_appoints_christopher_kaplan_to_its_strategic_advisory_board/2459110/Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and